Subepithelial connective tissue graft with growth factor for the treatment of maxillary gingival recession defects.
Gingival recession is a challenging defect for clinicians to treat effectively. A number of recent systematic reviews have identified the connective tissue graft (CTG) in combination with coronally advanced flaps (CAFs) as the most consistently effective treatment for Miller Class I and II defects across all outcome measures. Recent advances in recombinant growth factor technology may provide opportunities for improved outcomes in conjunction with CAF + CTG procedures. In this prospective consecutive case series, recombinant human platelet-derived growth factor BB (rhPDGF-BB) was combined with CTGs for the treatment of Miller Class I or II gingival recession defects. Improved outcomes were seen for keratinized tissue gains and percent root coverage at 6 months postsurgery when compared to historic norms. All other outcome parameters appeared equivalent between the two treatment approaches. The addition of rhPDGF-BB appeared to improve early wound healing as well.
bobrubbins@charlotteperio.com
Robert P
RP
Rubins
Paul N
PN
Tolmie
Kenneth T
KT
Corsig
Eric N
EN
Kerr
David M
DM
Kim
D000328:Adult; D043925:Angiogenesis Inducing Agents / Q000627:therapeutic use*; D000077214:Becaplermin; D003131:Combined Modality Therapy; D003238:Connective Tissue / Q000637:transplantation; D003774:Dental Plaque Index; D005260:Female; D005500:Follow-Up Studies; D005881:Gingiva / Q000187:drug effects / Q000473:pathology / Q000637:transplantation*; D005889:Gingival Recession / Q000188:drug therapy / Q000601:surgery*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017622:Periodontal Attachment Loss / Q000145:classification; D010512:Periodontal Index; D010514:Periodontal Pocket / Q000145:classification; D011446:Prospective Studies; D020574:Proto-Oncogene Proteins c-sis / Q000627:therapeutic use*; D011994:Recombinant Proteins; D013524:Surgical Flaps / Q000637:transplantation; D014092:Tooth Root / Q000601:surgery; D016896:Treatment Outcome; D014945:Wound Healing / Q000187:drug effects
D043925:Angiogenesis Inducing Agents; D020574:Proto-Oncogene Proteins c-sis; D011994:Recombinant Proteins; D000077214:Becaplermin